Povećanje zastupljenosti astrocita u hipokampusu 5xFAD miševa

Violeta Jovanović; Jelica Despotović; Mario Balo; Ivan  Zaletel; Sanja  Despotović; Nela Puškaš

doi:10.5937/mp72-32451

Violeta Jovanović Medicinski fakultet u Beogradu
Jelica Despotović Medicinski fakultet u Beogradu
Mario Balo Medicinski fakultet u Beogradu
doc. dr Ivan Zaletel Medicinski fakultet u Beogradu
doc. dr Sanja Despotović Medicinski fakultet u Beogradu
prof. dr Nela Puškaš Medicinski fakultet u Beogradu

DOI: https://doi.org/10.5937/mp72-32451

Ključne reči: Alchajmerova bolest, 5xFAD, hipokampus, astrociti, GFAP

Sažetak

Uvod: Alchajmerova bolest je najčešće neurodegenerativno oboljenje, koje se karakteriše formiranjem amiloidnih plakova i neurofibrilarne klubadi u mozgu obolelih osoba, što dovodi do oštećenja i gubitka neurona. Uporedo sa ovim procesom dolazi do aktivacije astrocita i astroglioze. Zbog etičkih ograničenja u radu sa humanim tkivom, za proučavanje patogeneze navedenih procesa razvijeni su brojni transgeni animalni modeli. Strukture koje najranije bivaju zahvaćene promenama jesu korteks i hipokampus.

Cilj rada: Cilj rada bio je utvrditi da li postoji razlika u zastupljenosti astrocita u hipokampusu između transgenih 5xFAD miševa starosti 36 nedelja i odgovarajućih kontrolnih jedinki.

Materijal i metode: Za potrebe istraživanja korišćen je 5xFAD model Alchajmerove bolesti, koji se karakteriše ranim formiranjem amiloidnih plakova, ali bez formiranja neurofibrilarne klubadi. Transgena i kontrolna grupa životinja žrtvovane su u 36. nedelji, a vizualizacija astrocita u tkivu hipokampusa urađena je imunohistohemijskom metodom pomoću antitela na glijalni kiseli fibrilarni protein – GFAP. Kvantifikacija zastupljenosti GFAP-pozitivnih ćelija je rađena korišćenjem Icy softvera.

Rezultati: Pokazana je statistički značajna razlika u prisustvu GFAP-pozitivnih ćelija u dentatnom girusu i granularnoj zoni hipokampusa između transgene i kontrolne grupe životinja, dok u CA1-3 regionima nije zapažena statistički značajna razlika između ispitivanih grupa.

Zaključak: Dobijeni rezultati jasno ukazuju na postojanje astoglioze kao bitnog mehanizma u patogenezi Alchajmerove bolesti kod 5xFAD miševa u 36. nedelji, ali i na raniju pojavu astroglioze u dentatnom girusu i granularnoj zoni u odnosu na ostale regione hipokampusa.

Reference

1. Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE et al. Alzheimer’s disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J Neurosci. 2014; 34(41): 13629–13643.
2. Zhiyou C, Cheng-Qun W, Zhou L. Astrocyte and Alzheimer’s disease. Journal of Neurology. 2017; 267: 2068-2074.
3. Voss JL, Bridge DJ, Cohen NJ, Walker JA. A Closer Look at the Hippocampus and Memory. Trends Cogn Sci. 2017; 21: 577-588.
4. Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D et al. Assessing the onset of structural change in familial Alzheimer’s disease. Ann Neurol. 2003; 87: 181-188.
5. Moodley KK, Chan D. The hippocampus in neurodegenerative disease. Front Neurol Neurosci. 2014; 44: 95-108.
6. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 34(41): 10129-40.
7. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119(1): 7-35.
8. Jo WK, Law AC, Chung SK. Neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogenesis of major neurodegenerative disorders. Mol Psychiatry. 2014; 19(2): 159-167.
9. Mancardi GL, Liwniez BH, Mandybur TI. Fibrous astrocytes in Alzheimer’s disease and senile dementia of Alzheimer’s type. Acta Neuropathol. 1983; 61(1): 76-80.
10. Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankovsky JL, Zheng H. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse models of Alzheimer’s Disease. J Neurosci. 2016; 34(41): 577-89.
11. Liu RX, Huang C, Bennett DA, Li H, Wang R. The characteristics of astrocyte on A clearance altered in Alzheimer’s disease were reversed by an anti-inflamatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res. 2016; 8(10): 4082-4094.
12. Olsen M, Aguilar X, Sehlin D, Fang XT, Antoni G, Erlandsson A et al. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s disease. Mol Imaging Biol. 2018; 20(4): 605-614.
13. Giarard SD, Jackuet M, Baranger K, Migliorati M, Escoffier G, Bernard A et al. Onset of hippocampus-dependent memory imparements in 5xFAD transgenic mouse model of Alzheimer’s disease. Hippocampus. 2014; 24: 762-772.
14. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006; 27(1): 67-77.
15. Hong I, Kang T, Yoo Y, Park R, Lee J, Lee S et al. Quantitative Proteomic Analysis of the Hippocampus in the 5xFAD Mouse Model at Early Stages of Alzheimer’s Disease Pathology. Journal of Alzheimer’s Disease. 2014; 36(2): 321–334.